HRT in Menopause: What Has Really Changed, and For Whom

For twenty years hormone replacement therapy was the treatment your doctor mentioned in a lowered voice, with the air of someone about to offer you something dangerous. Then, on 10 November 2025, the US FDA removed from menopausal oestrogen packaging the risk warnings that had accompanied it since 2003. This is not a piece of bureaucratic housekeeping: it is an official acknowledgement that those warnings had been badly written.

This guide explains what has actually changed and what has not, who is a candidate for hormone replacement therapy and who is not, and — if you belong to that large group of women for whom HRT is not possible or not the right choice — which natural supports have serious research behind them and which do not. With the clinical data in hand, not with opinions.

What hormone replacement therapy is

HRT — also called MHT, menopausal hormone therapy — replaces the hormones the ovary stops producing at menopause: mainly oestrogen, combined with a progestogen in women who still have a uterus. The progestogen is not there to treat symptoms: it is there to protect the endometrium, because oestrogen on its own would make it proliferate. That is precisely why women who have had a hysterectomy can take oestrogen alone.

Routes of administration are not equivalent

This is the part almost nobody explains properly, and it changes the risk profile more than the molecule itself does.

• Oral (tablets): the oestrogen passes through the liver before entering the bloodstream. That first-pass hepatic step alters the production of clotting factors and raises the risk of thrombosis.
• Transdermal (patches, gels, sprays): the oestrogen enters the blood directly and bypasses the liver. The thrombotic risk stays broadly comparable to that of women on no therapy at all.
• Local vaginal (low-dose creams, pessaries, rings): it acts only on genitourinary tissue, with minimal systemic absorption. For vaginal dryness and urinary symptoms it is often enough on its own, and it does not carry the risks of the systemic forms.

If you have read that "HRT increases the risk of thrombosis", the sentence is incomplete. The oral form increases it; the transdermal form does so far less. This is not an academic nuance: it is a conversation to have with your gynaecologist.

Why HRT is back at the centre of the debate

2002, and a press release written badly

In 2002 the Women's Health Initiative trial was stopped early and communicated with the emphasis placed on an increased risk of breast cancer. The effect was immediate: prescriptions collapsed across the Western world, and an entire generation of women went through menopause with no treatment at all.

The problem is that the average age of the participants was 63 years, and roughly two thirds of them were more than ten years past menopause. That trial measured what happens when you start therapy late, but the result was applied to everyone. The extended analysis published by Manson and colleagues in JAMA in 2013 (PMID 24084921), which followed the participants after they stopped treatment as well, showed a far more nuanced picture: absolute risks in the 50-59 age band were low, and in that group the balance of benefit and harm was favourable.

The window of opportunity

This is where what researchers call the timing hypothesis comes from: the same hormones behave differently depending on when you introduce them. In arteries that are still healthy, oestrogen appears to be protective; in arteries already affected by atherosclerotic plaque, it can destabilise them. The review by Mehta and colleagues (PMID 30484736) summarised this literature on the cardiovascular side.

In practice, the window is this: before the age of 60, or within ten years of your last period. Outside it, the arithmetic changes.

What the FDA decided in November 2025

On 10 November 2025 the FDA asked for the removal of the boxed warnings — the ones inside a black frame, the highest level of alert — covering cardiovascular disease, breast cancer and dementia from menopausal oestrogen products. The stated rationale: randomised trials show reductions in all-cause mortality and in fractures among women who start within ten years of menopause or before the age of 60.

Pay attention to what was not removed: the warning about endometrial cancer stays in place for systemic oestrogen-only products. That is consistent — the risk is real, and it is exactly why the progestogen exists.

It is worth saying honestly: removing a warning does not mean the therapy carries no risk. It means those warnings, phrased in an undifferentiated way, communicated badly a risk that depends on age, on route of administration and on clinical history. This is a correction to how the information was communicated, not a promotion.

HRT and bioidentical hormones: where the real difference lies

"Bioidentical" means the molecule has the same chemical structure as the one the human body produces. Bioidentical oestradiol and micronised progesterone fall under this definition, and they are available as approved, industrially manufactured medicines.

The term, though, is also used for something else: compounded preparations, made up to measure by a pharmacy, often promoted alongside salivary hormone testing and promises of therapy tailored to you. This is where the evidence stops.

The clinical consensus of the American College of Obstetricians and Gynecologists (PMID 37856860) is explicit on the point: compounded bioidentical preparations have not been shown to be either safer or more effective than approved products, they are not subject to the same purity and dosing controls, and salivary testing has no clinical value for guiding therapy. The review by Stanczyk in Climacteric (PMID 33403887) reaches the same conclusion from the pharmacological side.

In short: if what appeals to you is a molecule identical to your own, it already exists as a licensed medicine. The version compounded to measure is not more natural — it is simply less controlled.

Who is a candidate for HRT

The recognised indications are essentially three:

• Moderate to severe vasomotor symptoms — hot flashes and night sweats that interfere with sleep, work and daily life. This is the main indication, and HRT remains the most effective treatment that exists for this symptom.
• Genitourinary syndrome of menopause — vaginal dryness, pain during sex, recurrent urinary problems. Here local vaginal oestrogen is often enough.
• Prevention of osteoporosis in women at high risk, in early menopause, or in any case still inside the window before 60.

There is also a particular case that deserves attention: early menopause, before 45, and premature ovarian insufficiency. In these situations therapy is not an option chosen for comfort, it is the replacement of something the body should still be producing, and it is generally recommended up to the physiological age of menopause.

Who is not a candidate

The absolute contraindications are few but clear-cut:

• Current or previous breast cancer
• Hormone-sensitive endometrial cancer
• Vaginal bleeding of unexplained cause
• Recent venous thromboembolism or known thrombophilia
• Recent heart attack or stroke
• Active liver disease

Then there are the in-between situations — migraine with aura, uncontrolled hypertension, gallstones, fibroids, a strong family history of cancer — where the decision is not automatic and depends on the individual balance, often leaning towards the transdermal route.

This group, added to the women who simply do not want to take hormones, is anything but marginal. In Italy it is estimated that fewer than one in ten women in menopause are on hormone therapy. That is exactly the audience the search results leave uncovered: you find dozens of pages explaining HRT, and almost nothing serious about what to do if HRT is not your path.

What actually works if you are not on HRT

Here we need to be honest about the hierarchy of evidence. None of these options matches hormone therapy for effectiveness against severe hot flashes. Some of them, however, have genuine controlled trials behind them, and on mild to moderate symptoms they are a reasonable alternative.

Soy isoflavones — the strongest evidence of the group

They are phytoestrogens: plant molecules that bind weakly to oestrogen receptors. The meta-analysis by Franco and colleagues published in JAMA in 2016 (PMID 27327802), which pooled the trials on plant-based therapies, found a modest but statistically significant improvement in hot flashes, with a standardised mean difference of around -0.35. The specific meta-analysis by Taku in Menopause (PMID 22433977) estimated reductions of roughly 20% in hot flash frequency compared with placebo.

Modest means modest: do not expect them to disappear. But for mild hot flashes, and with a favourable safety profile, this is the option with the most data behind it. We covered it in detail in our piece on soy isoflavones in menopause, including the reason why they help with symptoms but do not protect bone.

Cimicifuga racemosa

The review with meta-analysis by Castelo-Branco in Climacteric (PMID 33021111), focused on the standardised isopropanolic extract, reports an improvement in menopausal symptoms compared with placebo. It has to be said that the overall literature on black cohosh is inconsistent and depends heavily on the extract used: the positive results cluster around standardised preparations, not around the generic plant. We have devoted a whole article to cimicifuga for menopausal symptoms.

Salvia officinalis

Less well known, but with one interesting finding: the study by Bommer in 2011 (PMID 21630133) in 71 menopausal women reported a 64% reduction in hot flashes over eight weeks, with good tolerability. It is a single study with no placebo arm, so the figure should be taken for what it is — a signal, not definitive proof.

The lesser-known options, and which symptom they actually act on

The three we have just looked at all target hot flashes. But menopause is not only hot flashes, and some of the things that work best act on symptoms that get talked about far less.

Curcumin and vitamin E

A triple-blind RCT by Ataei-Almanghadim (PMID 31987231) in postmenopausal women tested curcumin and vitamin E against placebo, finding a reduction in the frequency of hot flashes and an improvement in anxiety. A small study, but methodologically clean.

Magnesium — the right symptom

Magnesium does not act on hot flashes, and anyone telling you otherwise is selling a good product badly. It acts on what often makes menopause unbearable more than the hot flashes themselves do: insomnia, irritability, muscle tension, tiredness. These are claims recognised at European level — magnesium contributes to the reduction of tiredness and fatigue and contributes to the normal functioning of the nervous system.

And cortisol

There is one piece of the puzzle that is almost always ignored. Falling oestrogen often comes with a less well-regulated stress response, and that feeds a loop which worsens sleep, mood and abdominal fat accumulation. We looked at it in depth in cortisol and menopausal stress, and it is worth reading if you recognise yourself more in "I am exhausted and I cannot sleep" than in "I am getting hot flashes".

The natural programme we recommend

Not every symptom responds to the same thing. It makes sense to start from whatever is bothering you most, rather than taking everything at once.

If hot flashes are the problem

Our Menopause Hot Flashes Relief is built on isoflavones — the molecule with the best evidence in the group — combined with Moringa oleifera for its micronutrient content. It is the formulation we recommend to women with mild to moderate hot flashes who are not on hormone therapy, or who take it alongside HRT with their gynaecologist's agreement. You will find the full rationale in our guide on how to eliminate menopause hot flashes.

If you prefer a more stripped-back formula, there is the Hot Flashes Supplement with Isoflavones and Moringa, the same logic in a simpler version.

If sleep and nervous tension are the problem

Magnesium Bisglycinate with Vitamin D3 and B6 is the most sensible choice. The bisglycinate form is chelated to an amino acid and is better tolerated by the gut than magnesium oxide, which is what you find in most supermarket products and which frequently achieves nothing except a laxative effect.

If chronic stress is the problem

Phosphatidylserine and Moringa works on the cortisol response, and it is the one to consider when the dominant feeling is of being permanently under pressure, with broken sleep and difficulty concentrating.

Energy, desire and the micronutrient base

Two items remain that do not fit the logic of a single dominant symptom, but which in practice make a real difference to how you feel across the day.

If energy and desire are the problem

Black maca is the adaptogen with the longest tradition of use for female energy and libido, and it is the heart of INCA FORCE Black Maca. If you want to understand what the research actually says before trying it, we have written a dedicated guide to maca for women in menopause.

The base

Organic Moringa Oleifera capsules are not a menopause remedy and we do not present them as one. They are a supply of micronutrients — calcium, iron, B-group vitamins — for the rest to rest on, at a stage of life when your requirements shift. On diet as a whole, our article on what to eat during perimenopause and menopause goes into detail, and the one on how to lose weight during menopause tackles weight, which is the second reason women write to us.

How to decide, and with whom

HRT is a prescription therapy and the decision belongs to your gynaecologist, not to an article. What you can do is turn up to the appointment prepared.

It is worth asking: am I inside the ten-year window? Is there anything in my clinical history that rules it out? Does the transdermal route make more sense than the oral one for me? If my main symptom is vaginal dryness, is local oestrogen enough? And — the question almost nobody asks — how often do we review this?

If the answer is that the therapy is not for you, you are not without options. You are simply in territory where improvements are more gradual and have to be built on the right symptom. If that symptom is hot flashes, Menopause Hot Flashes Relief is where we would start. From natural supports, expect a benefit over a span of eight to twelve weeks, not in a week: if nothing has changed after three months, change strategy instead of persisting.

Frequently asked questions

Does hormone replacement therapy cause breast cancer?

In November 2025 the FDA removed the boxed warning on breast cancer from menopausal oestrogen products, judging it to have been worded in a misleading way. This does not mean zero risk: it means the risk depends on the age at which you start, on duration, on the type of progestogen combined with it and on your personal history, and that communicating it as a uniform danger for every woman was wrong. Previous breast cancer remains an absolute contraindication.

At what age can you start HRT?

The window considered favourable is before the age of 60, or within ten years of your last period. Starting inside this window is associated with a better risk-benefit balance, particularly on the cardiovascular side. Starting much later changes the arithmetic and calls for an individual assessment.

How long can you stay on it?

There is no longer a fixed maximum duration that applies to everyone. The current approach is to use the lowest effective dose for as long as it is needed, reviewing it periodically with your gynaecologist. In early menopause, therapy is generally continued at least until the age at which menopause would have arrived naturally.

Can isoflavones replace hormone therapy?

No, and anyone who claims otherwise is overstating the case. Meta-analyses show a modest improvement in hot flashes, around a 20% reduction in frequency compared with placebo: useful for mild or moderate symptoms, not comparable to the effect of oestrogen on severe hot flashes. They are a reasonable option for women who cannot or do not want to take HRT, not an equivalent of it.

Can I take natural supplements alongside hormone therapy?

Discuss it with your gynaecologist, because it depends on what you are taking. Magnesium and micronutrients generally pose no problem. With phytoestrogens the question is different: they act on the same receptors as the therapy, so the combination has to be assessed case by case, particularly if you have a history of hormone-sensitive cancer.

Are there contraindications to natural supports for menopause?

Yes. Isoflavones and other phytoestrogens are not advised if you have or have had a hormone-sensitive cancer. Cimicifuga calls for caution where there is liver disease. Both should be avoided during pregnancy and breastfeeding. If you take medication long term — anticoagulants, thyroid hormones or cancer treatments in particular — talk to your doctor first.